Insilico caps the year with a soaring Hong Kong IPO

FierceBiotechClinical-stage cancer biotech Treeline sees path to public markets via reverse merger

FierceBiotechADA: Dexcom CGM shows benefit in non-insulin diabetes patients

Endpoints NewsTreeline to go public via reverse merger with Standard BioTools

FierceBiotechResmed snaps up Noctrix Health in $340M sleep tech deal

BioWorldBiggest gainers and losers for June 1-5, 2026

Endpoints NewsJ&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS field

FierceBiotechJ&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Endpoints NewsGSK inks multi-target pact with Engitix; Sangamo considers strategic options

Endpoints NewsTango plans Phase 3 pancreatic cancer study after combo success

Endpoints NewsComing Soon

Endpoints NewsBiopharma's top-paid CEOs of 2025: 25 making $25M+

Endpoints NewsCavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugs